Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Aug 1;100(3):530–537. doi: 10.1172/JCI119562

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

M K Cavaghan 1, D A Ehrmann 1, M M Byrne 1, K S Polonsky 1
PMCID: PMC508219  PMID: 9239399

Abstract

Impaired glucose tolerance (IGT) is associated with defects in both insulin secretion and action and carries a high risk for conversion to non-insulin-dependent diabetes mellitus (NIDDM). Troglitazone, an insulin sensitizing agent, reduces glucose concentrations in subjects with NIDDM and IGT but is not known to affect insulin secretion. We sought to determine the role of beta cell function in mediating improved glucose tolerance. Obese subjects with IGT received 12 wk of either 400 mg daily of troglitazone (n = 14) or placebo (n = 7) in a randomized, double-blind design. Study measures at baseline and after treatment were glucose and insulin responses to a 75-g oral glucose tolerance test, insulin sensitivity index (SI) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion rates during a graded glucose infusion, and beta cell glucose-sensing ability during an oscillatory glucose infusion. Troglitazone reduced integrated glucose and insulin responses to oral glucose by 10% (P = 0.03) and 39% (P = 0.003), respectively. SI increased from 1.3+/-0.3 to 2.6+/-0.4 x 10(-)5min-1pM-1 (P = 0.005). Average insulin secretion rates adjusted for SI over the glucose interval 5-11 mmol/liter were increased by 52% (P = 0.02), and the ability of the beta cell to entrain to an exogenous oscillatory glucose infusion, as evaluated by analysis of spectral power, was improved by 49% (P = 0.04). No significant changes in these parameters were demonstrated in the placebo group. In addition to increasing insulin sensitivity, we demonstrate that troglitazone improves the reduced beta cell response to glucose characteristic of subjects with IGT. This appears to be an important factor in the observed improvement in glucose tolerance.

Full Text

The Full Text of this article is available as a PDF (193.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergman R. N. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989 Dec;38(12):1512–1527. doi: 10.2337/diab.38.12.1512. [DOI] [PubMed] [Google Scholar]
  2. Bergman R. N., Phillips L. S., Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981 Dec;68(6):1456–1467. doi: 10.1172/JCI110398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berkowitz K., Peters R., Kjos S. L., Goico J., Marroquin A., Dunn M. E., Xiang A., Azen S., Buchanan T. A. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 1996 Nov;45(11):1572–1579. doi: 10.2337/diab.45.11.1572. [DOI] [PubMed] [Google Scholar]
  4. Brandes R., Arad R., Bar-Tana J. Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells. Biochem Pharmacol. 1995 Nov 27;50(11):1949–1951. doi: 10.1016/0006-2952(95)02082-9. [DOI] [PubMed] [Google Scholar]
  5. Byrne M. M., Sturis J., Clément K., Vionnet N., Pueyo M. E., Stoffel M., Takeda J., Passa P., Cohen D., Bell G. I. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest. 1994 Mar;93(3):1120–1130. doi: 10.1172/JCI117064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Byrne M. M., Sturis J., Polonsky K. S. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol. 1995 Jan;268(1 Pt 1):E21–E27. doi: 10.1152/ajpendo.1995.268.1.E21. [DOI] [PubMed] [Google Scholar]
  7. Byrne M. M., Sturis J., Sobel R. J., Polonsky K. S. Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function. Am J Physiol. 1996 Apr;270(4 Pt 1):E572–E579. doi: 10.1152/ajpendo.1996.270.4.E572. [DOI] [PubMed] [Google Scholar]
  8. DeFronzo R. A., Bonadonna R. C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992 Mar;15(3):318–368. doi: 10.2337/diacare.15.3.318. [DOI] [PubMed] [Google Scholar]
  9. Dunaif A., Finegood D. T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996 Mar;81(3):942–947. doi: 10.1210/jcem.81.3.8772555. [DOI] [PubMed] [Google Scholar]
  10. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996 Sep;81(9):3299–3306. doi: 10.1210/jcem.81.9.8784087. [DOI] [PubMed] [Google Scholar]
  11. Eaton R. P., Allen R. C., Schade D. S., Erickson K. M., Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab. 1980 Sep;51(3):520–528. doi: 10.1210/jcem-51-3-520. [DOI] [PubMed] [Google Scholar]
  12. Edelstein S. L., Knowler W. C., Bain R. P., Andres R., Barrett-Connor E. L., Dowse G. K., Haffner S. M., Pettitt D. J., Sorkin J. D., Muller D. C. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997 Apr;46(4):701–710. doi: 10.2337/diab.46.4.701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ehrmann D. A., Sturis J., Byrne M. M., Karrison T., Rosenfield R. L., Polonsky K. S. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul;96(1):520–527. doi: 10.1172/JCI118064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Elks M. L. Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology. 1993 Jul;133(1):208–214. doi: 10.1210/endo.133.1.8319569. [DOI] [PubMed] [Google Scholar]
  15. Eriksson J., Franssila-Kallunki A., Ekstrand A., Saloranta C., Widén E., Schalin C., Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989 Aug 10;321(6):337–343. doi: 10.1056/NEJM198908103210601. [DOI] [PubMed] [Google Scholar]
  16. Eriksson K. F., Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia. 1991 Dec;34(12):891–898. doi: 10.1007/BF00400196. [DOI] [PubMed] [Google Scholar]
  17. Faber O. K., Binder C., Markussen J., Heding L. G., Naithani V. K., Kuzuya H., Blix P., Horwitz D. L., Rubenstein A. H. Characterization of seven C-peptide antisera. Diabetes. 1978;27 (Suppl 1):170–177. doi: 10.2337/diab.27.1.s170. [DOI] [PubMed] [Google Scholar]
  18. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988 Nov;37(11):1549–1558. doi: 10.2337/diab.37.11.1549. [DOI] [PubMed] [Google Scholar]
  19. Haffner S. M., Stern M. P., Hazuda H. P., Mitchell B. D., Patterson J. K. Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med. 1988 Nov 17;319(20):1297–1301. doi: 10.1056/NEJM198811173192001. [DOI] [PubMed] [Google Scholar]
  20. Helmrich S. P., Ragland D. R., Leung R. W., Paffenbarger R. S., Jr Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991 Jul 18;325(3):147–152. doi: 10.1056/NEJM199107183250302. [DOI] [PubMed] [Google Scholar]
  21. Hidaka H., Nagulesparan M., Klimes I., Clark R., Sasaki H., Aronoff S. L., Vasquez B., Rubenstein A. H., Unger R. H. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J Clin Endocrinol Metab. 1982 Feb;54(2):217–222. doi: 10.1210/jcem-54-2-217. [DOI] [PubMed] [Google Scholar]
  22. Ibrahimi A., Teboul L., Gaillard D., Amri E. Z., Ailhaud G., Young P., Cawthorne M. A., Grimaldi P. A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol. 1994 Dec;46(6):1070–1076. [PubMed] [Google Scholar]
  23. Inoue I., Takahashi K., Katayama S., Harada Y., Negishi K., Itabashi A., Ishii J. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats. Metabolism. 1995 Dec;44(12):1626–1630. doi: 10.1016/0026-0495(95)90085-3. [DOI] [PubMed] [Google Scholar]
  24. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996 Feb;19(2):151–156. doi: 10.2337/diacare.19.2.151. [DOI] [PubMed] [Google Scholar]
  25. Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991 Nov;14(11):1083–1086. doi: 10.2337/diacare.14.11.1083. [DOI] [PubMed] [Google Scholar]
  26. Kahn S. E., Prigeon R. L., McCulloch D. K., Boyko E. J., Bergman R. N., Schwartz M. W., Neifing J. L., Ward W. K., Beard J. C., Palmer J. P. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993 Nov;42(11):1663–1672. doi: 10.2337/diab.42.11.1663. [DOI] [PubMed] [Google Scholar]
  27. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995 Dec 1;83(5):813–819. doi: 10.1016/0092-8674(95)90194-9. [DOI] [PubMed] [Google Scholar]
  28. Kosaka K., Kuzuya T., Akanuma Y., Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia. 1980 Jan;18(1):23–28. doi: 10.1007/BF01228297. [DOI] [PubMed] [Google Scholar]
  29. Leahy J. L., Bonner-Weir S., Weir G. C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care. 1992 Mar;15(3):442–455. doi: 10.2337/diacare.15.3.442. [DOI] [PubMed] [Google Scholar]
  30. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953–12956. doi: 10.1074/jbc.270.22.12953. [DOI] [PubMed] [Google Scholar]
  31. Lillioja S., Mott D. M., Howard B. V., Bennett P. H., Yki-Järvinen H., Freymond D., Nyomba B. L., Zurlo F., Swinburn B., Bogardus C. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med. 1988 May 12;318(19):1217–1225. doi: 10.1056/NEJM198805123181901. [DOI] [PubMed] [Google Scholar]
  32. Long S. D., O'Brien K., MacDonald K. G., Jr, Leggett-Frazier N., Swanson M. S., Pories W. J., Caro J. F. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 1994 May;17(5):372–375. doi: 10.2337/diacare.17.5.372. [DOI] [PubMed] [Google Scholar]
  33. McGarry J. D. Disordered metabolism in diabetes: have we underemphasized the fat component? J Cell Biochem. 1994;55 (Suppl):29–38. doi: 10.1002/jcb.240550005. [DOI] [PubMed] [Google Scholar]
  34. Melander A., Bitzén P. O., Sartor G., Scherstén B., Wåhlin-Boll E. Will sulfonylurea treatment of impaired glucose tolerance delay development and complications of NIDDM? Diabetes Care. 1990 Aug;13 (Suppl 3):53–58. doi: 10.2337/diacare.13.3.53. [DOI] [PubMed] [Google Scholar]
  35. Nolan J. J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994 Nov 3;331(18):1188–1193. doi: 10.1056/NEJM199411033311803. [DOI] [PubMed] [Google Scholar]
  36. O'Meara N. M., Sturis J., Van Cauter E., Polonsky K. S. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest. 1993 Jul;92(1):262–271. doi: 10.1172/JCI116560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Polonsky K. S., Given B. D., Hirsch L. J., Tillil H., Shapiro E. T., Beebe C., Frank B. H., Galloway J. A., Van Cauter E. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 May 12;318(19):1231–1239. doi: 10.1056/NEJM198805123181903. [DOI] [PubMed] [Google Scholar]
  38. Polonsky K. S., Licinio-Paixao J., Given B. D., Pugh W., Rue P., Galloway J., Karrison T., Frank B. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan;77(1):98–105. doi: 10.1172/JCI112308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Polonsky K. S. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995 Jun;44(6):705–717. doi: 10.2337/diab.44.6.705. [DOI] [PubMed] [Google Scholar]
  40. Porte D., Jr Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes. 1991 Feb;40(2):166–180. doi: 10.2337/diab.40.2.166. [DOI] [PubMed] [Google Scholar]
  41. Rossetti L., Giaccari A., DeFronzo R. A. Glucose toxicity. Diabetes Care. 1990 Jun;13(6):610–630. doi: 10.2337/diacare.13.6.610. [DOI] [PubMed] [Google Scholar]
  42. Sako Y., Grill V. E. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology. 1990 Oct;127(4):1580–1589. doi: 10.1210/endo-127-4-1580. [DOI] [PubMed] [Google Scholar]
  43. Scheen A. J., Letiexhe M. R., Lefèbvre P. J. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med. 1995 Nov;12(11):985–989. doi: 10.1111/j.1464-5491.1995.tb00410.x. [DOI] [PubMed] [Google Scholar]
  44. Sreenan S., Sturis J., Pugh W., Burant C. F., Polonsky K. S. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol. 1996 Oct;271(4 Pt 1):E742–E747. doi: 10.1152/ajpendo.1996.271.4.E742. [DOI] [PubMed] [Google Scholar]
  45. Stein D. T., Esser V., Stevenson B. E., Lane K. E., Whiteside J. H., Daniels M. B., Chen S., McGarry J. D. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest. 1996 Jun 15;97(12):2728–2735. doi: 10.1172/JCI118727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sturis J., Pugh W. L., Tang J., Polonsky K. S. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am J Physiol. 1995 Oct;269(4 Pt 1):E786–E792. doi: 10.1152/ajpendo.1995.269.4.E786. [DOI] [PubMed] [Google Scholar]
  47. Sturis J., Van Cauter E., Blackman J. D., Polonsky K. S. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest. 1991 Feb;87(2):439–445. doi: 10.1172/JCI115015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Suter S. L., Nolan J. J., Wallace P., Gumbiner B., Olefsky J. M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992 Feb;15(2):193–203. doi: 10.2337/diacare.15.2.193. [DOI] [PubMed] [Google Scholar]
  49. Unger R. H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995 Aug;44(8):863–870. doi: 10.2337/diab.44.8.863. [DOI] [PubMed] [Google Scholar]
  50. Vague P., Moulin J. P. The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism. 1982 Feb;31(2):139–142. doi: 10.1016/0026-0495(82)90125-1. [DOI] [PubMed] [Google Scholar]
  51. Van Cauter E., Mestrez F., Sturis J., Polonsky K. S. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992 Mar;41(3):368–377. doi: 10.2337/diab.41.3.368. [DOI] [PubMed] [Google Scholar]
  52. Warram J. H., Martin B. C., Krolewski A. S., Soeldner J. S., Kahn C. R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990 Dec 15;113(12):909–915. doi: 10.7326/0003-4819-113-12-909. [DOI] [PubMed] [Google Scholar]
  53. Weir G. C. Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. Am J Med. 1982 Oct;73(4):461–464. doi: 10.1016/0002-9343(82)90321-7. [DOI] [PubMed] [Google Scholar]
  54. Yki-Järvinen H. Glucose toxicity. Endocr Rev. 1992 Aug;13(3):415–431. doi: 10.1210/edrv-13-3-415. [DOI] [PubMed] [Google Scholar]
  55. Zhou Y. P., Grill V. E. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest. 1994 Feb;93(2):870–876. doi: 10.1172/JCI117042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. de Souza C. J., Yu J. H., Robinson D. D., Ulrich R. G., Meglasson M. D. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes. 1995 Aug;44(8):984–991. doi: 10.2337/diab.44.8.984. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES